|
Glaxo set to submit Relovair to regulatory authorities
ShareCast Additionally, all but one of the pivotal studies in patients with asthma have been completed. For COPD, Glaxo intends to submit regulatory applications in the US and Europe in mid-2012. For asthma, Glaxo plans to submit an application in Europe in … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … |
View full post on asthma – Google News